2017 Sternfels Prize Winner
Merrie Mosedale, PhD
UNC Eshelman School of Pharmacy
HLA-based mechanisms of drug-induced liver injury (DILI)
2017 Honerable Mentions
Jai Patel, PharmD
Genotype-based immunosuppression strategies for stem cell transplant patients
Kevin Kobylinski, PhD
Novel malaria vector control measures by treating humans with drugs
Each new pharmaceutical is a life-changing technological wonder. The Sternfels Prize was created to reduce the risk associated with the real-world use of pharmaceuticals. The purpose of the prize is to incentivize pharmacologists, pharmacists, medical practitioners, academics, and students to think about ways to reduce the real world risks patients face from polypharmacy, interacting co-morbidities, and genetic variations.
The prize is awarded to the most novel, important, and testable idea to reduce life threatening drug-drug, drug-disease or pharmacogenomic interactions. All submissions must be the applicant’s own work and not already be adequately addressed on an existing drug label or in a scholarly work. The winning submission received $35,000 (USD).
The Sternfels Prize is named in honor of Edith and Ernst Sternfels. Ernst was an engineer involved in the design and construction of chemical plants around the world, including many involved in the synthesis of life-improving molecules. Edith was a nurse, dedicated to the welfare and treatment of patients. Together, they represent the wingspan of modern medicine, from highly technical science to personal attention and care.
While major advances have been made across this spectrum, the Sternfels Prize was created to help fill in places where human ingenuity and observation can shave away unnecessary risk associated with the real-world use of pharmaceuticals. It is awarded to the most important and testable idea to reduce life threatening drug-drug, drug-disease or pharmacogenomic interactions. The current prize stands at $35,000 (USD).